{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(9)"],"submitter":["Bhan V"],"funding":["Novartis Canada"],"pubmed_abstract":["<b>Aim:</b> The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. <b>Materials & methods:</b> A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined ofatumumab as first-line treatment versus 3 and 5 years following switch from commonly used first-line therapies. <b>Results:</b> Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes. <b>Conclusion:</b> Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease."],"journal":["Journal of comparative effectiveness research"],"pagination":["e220175"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690431"],"repository":["biostudies-literature"],"pubmed_title":["Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada."],"pmcid":["PMC10690431"],"pubmed_authors":["Vudumula U","Patel BP","Mouallif S","Adlard N","Grima D","Thomas K","Bhan V","Clift F","Blanchette F","Gudala K","Dutta N","Farhane F","Baharnoori M"],"additional_accession":[]},"is_claimable":false,"name":"Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.","description":"<b>Aim:</b> The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. <b>Materials & methods:</b> A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined ofatumumab as first-line treatment versus 3 and 5 years following switch from commonly used first-line therapies. <b>Results:</b> Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes. <b>Conclusion:</b> Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2026-05-28T21:35:10.433Z","creation":"2025-04-19T20:19:50.393Z"},"accession":"S-EPMC10690431","cross_references":{"pubmed":["37606897"],"doi":["10.57264/cer-2022-0175"]}}